NO329546B1 - Fremgangsmate for reverstranskribering og detektering av HCV-RNA, oligonukleotid egnet for bruk i nevnte fremgangsmate samt kit inneholdende nevnte oligonukleotid. - Google Patents
Fremgangsmate for reverstranskribering og detektering av HCV-RNA, oligonukleotid egnet for bruk i nevnte fremgangsmate samt kit inneholdende nevnte oligonukleotid. Download PDFInfo
- Publication number
- NO329546B1 NO329546B1 NO20000537A NO20000537A NO329546B1 NO 329546 B1 NO329546 B1 NO 329546B1 NO 20000537 A NO20000537 A NO 20000537A NO 20000537 A NO20000537 A NO 20000537A NO 329546 B1 NO329546 B1 NO 329546B1
- Authority
- NO
- Norway
- Prior art keywords
- seq
- hcv
- rna
- reverse transcription
- detection
- Prior art date
Links
- 238000010839 reverse transcription Methods 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 46
- 238000001514 detection method Methods 0.000 title claims description 30
- 108091034117 Oligonucleotide Proteins 0.000 title claims description 23
- 241000711549 Hepacivirus C Species 0.000 claims abstract description 89
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 22
- 239000012472 biological sample Substances 0.000 claims abstract description 17
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 37
- 230000003321 amplification Effects 0.000 claims description 36
- 238000006243 chemical reaction Methods 0.000 claims description 29
- 238000003752 polymerase chain reaction Methods 0.000 claims description 26
- 239000000523 sample Substances 0.000 claims description 25
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 210000002381 plasma Anatomy 0.000 claims description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 238000001502 gel electrophoresis Methods 0.000 claims description 3
- 238000007834 ligase chain reaction Methods 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 230000037429 base substitution Effects 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- 238000000246 agarose gel electrophoresis Methods 0.000 claims 1
- 239000003155 DNA primer Substances 0.000 abstract description 2
- 239000013615 primer Substances 0.000 description 90
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 50
- 102100034349 Integrase Human genes 0.000 description 38
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 37
- 239000000047 product Substances 0.000 description 25
- 230000002441 reversible effect Effects 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000013641 positive control Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 108091092724 Noncoding DNA Proteins 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- -1 phosphotriesters Chemical class 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000711557 Hepacivirus Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000011896 sensitive detection Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019791 Hepatitis post transfusion Diseases 0.000 description 1
- 101710125507 Integrase/recombinase Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000012162 RNA isolation reagent Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/10—Nucleotidyl transfering
- C12Q2521/107—RNA dependent DNA polymerase,(i.e. reverse transcriptase)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11852099P | 1999-02-03 | 1999-02-03 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20000537D0 NO20000537D0 (no) | 2000-02-02 |
NO20000537L NO20000537L (no) | 2000-08-04 |
NO329546B1 true NO329546B1 (no) | 2010-11-08 |
Family
ID=22379122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20000537A NO329546B1 (no) | 1999-02-03 | 2000-02-02 | Fremgangsmate for reverstranskribering og detektering av HCV-RNA, oligonukleotid egnet for bruk i nevnte fremgangsmate samt kit inneholdende nevnte oligonukleotid. |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1036847B1 (ja) |
JP (1) | JP4624515B2 (ja) |
KR (1) | KR100683427B1 (ja) |
CN (1) | CN1201017C (ja) |
AT (1) | ATE280839T1 (ja) |
AU (1) | AU783309C (ja) |
CA (1) | CA2296072C (ja) |
CY (1) | CY1105473T1 (ja) |
DE (1) | DE60015210T2 (ja) |
DK (1) | DK1036847T3 (ja) |
ES (1) | ES2230027T3 (ja) |
NO (1) | NO329546B1 (ja) |
PT (1) | PT1036847E (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100543132C (zh) * | 2003-03-24 | 2009-09-23 | 香港大学 | 引起严重急性呼吸道综合征(sars)的新型人病毒及其应用 |
EP2147118A4 (en) * | 2007-04-27 | 2010-09-01 | Eragen Biosciences Inc | MATERIALS AND METHOD FOR DETECTING HEPATITIS C VIRUS |
CN101660004B (zh) * | 2009-07-03 | 2012-06-06 | 广东药学院 | 贝类gⅱ型扎幌样病毒检测用的引物、探针、检测方法及试剂盒 |
CN102154510B (zh) * | 2011-02-25 | 2013-01-16 | 湖南圣湘生物科技有限公司 | 丙型肝炎病毒核酸定量检测试剂盒 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09107970A (ja) * | 1995-10-17 | 1997-04-28 | Soyaku Gijutsu Kenkyusho:Kk | C型肝炎ウイルス由来核酸、該核酸を用いたウイルスの検出方法 |
JPH06153961A (ja) * | 1992-11-27 | 1994-06-03 | Imuno Japan:Kk | C型肝炎ウイルス部分遺伝子、ならびにc型肝炎ウイルス遺 伝子の高感度検出法 |
US5874565A (en) * | 1995-08-29 | 1999-02-23 | Washington University | Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus |
US5837442A (en) * | 1995-11-29 | 1998-11-17 | Roche Molecular Systems, Inc. | Oligonucleotide primers for amplifying HCV nucleic acid |
US6153421A (en) * | 1997-07-18 | 2000-11-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Cloned genomes of infectious hepatitis C viruses and uses thereof |
-
2000
- 2000-02-01 ES ES00300791T patent/ES2230027T3/es not_active Expired - Lifetime
- 2000-02-01 PT PT00300791T patent/PT1036847E/pt unknown
- 2000-02-01 DE DE60015210T patent/DE60015210T2/de not_active Expired - Lifetime
- 2000-02-01 CA CA002296072A patent/CA2296072C/en not_active Expired - Fee Related
- 2000-02-01 EP EP20000300791 patent/EP1036847B1/en not_active Expired - Lifetime
- 2000-02-01 DK DK00300791T patent/DK1036847T3/da active
- 2000-02-01 AT AT00300791T patent/ATE280839T1/de active
- 2000-02-02 KR KR1020000005171A patent/KR100683427B1/ko not_active IP Right Cessation
- 2000-02-02 AU AU14876/00A patent/AU783309C/en not_active Ceased
- 2000-02-02 NO NO20000537A patent/NO329546B1/no not_active IP Right Cessation
- 2000-02-03 CN CNB001041797A patent/CN1201017C/zh not_active Expired - Fee Related
- 2000-02-03 JP JP2000032657A patent/JP4624515B2/ja not_active Expired - Fee Related
-
2005
- 2005-01-10 CY CY20051100038T patent/CY1105473T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CN1270228A (zh) | 2000-10-18 |
ES2230027T3 (es) | 2005-05-01 |
AU783309C (en) | 2006-08-17 |
CY1105473T1 (el) | 2010-04-28 |
PT1036847E (pt) | 2005-01-31 |
AU1487600A (en) | 2000-08-10 |
CA2296072C (en) | 2008-06-03 |
DE60015210T2 (de) | 2006-02-16 |
CN1201017C (zh) | 2005-05-11 |
KR100683427B1 (ko) | 2007-02-20 |
EP1036847A1 (en) | 2000-09-20 |
AU783309B2 (en) | 2005-10-13 |
NO20000537L (no) | 2000-08-04 |
DK1036847T3 (da) | 2005-02-07 |
CA2296072A1 (en) | 2000-08-03 |
KR20000076597A (ko) | 2000-12-26 |
DE60015210D1 (de) | 2004-12-02 |
JP2000350589A (ja) | 2000-12-19 |
NO20000537D0 (no) | 2000-02-02 |
JP4624515B2 (ja) | 2011-02-02 |
EP1036847B1 (en) | 2004-10-27 |
ATE280839T1 (de) | 2004-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5450914B2 (ja) | C型肝炎ウイルス(hcv)の効率的検出のためのオリゴヌクレオチドプライマーおよびそれの使用 | |
Schlueter et al. | Reverse transcription-PCR detection of hepatitis G virus | |
CA2957200C (en) | Compositions and methods for detecting west nile virus | |
KR100901084B1 (ko) | Hiv-1 및 hiv-2를 효율적으로 검출하기 위한 올리고뉴클레오타이드 역전사 프라이머, 이의 사용 방법 및 이를 포함하는 키트 | |
EP1035220B1 (en) | Oligonucleotide primers for efficient multiplex detection of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) and methods of use thereof | |
WO2017164741A2 (en) | Detection of zika virus nucleic acid | |
NO329546B1 (no) | Fremgangsmate for reverstranskribering og detektering av HCV-RNA, oligonukleotid egnet for bruk i nevnte fremgangsmate samt kit inneholdende nevnte oligonukleotid. | |
WO2015150083A1 (en) | Method for specific detection of classical swine fever virus | |
JP5315519B2 (ja) | コイヘルペスウイルス(khv)の検出方法 | |
AU2006203092B2 (en) | Oligonucleotide primers for efficient detection of hepatitis C virus (HCV) and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |